Ravicti approved for urea cycle disorders

(HealthDay)—Ravicti (glycerol phenylbutyrate) has been approved by the U.S. Food and Drug Administration to treat certain urea cycle disorders (UCDs) in people 2 years and older.

These inherited conditions involve a lack of enzymes that help the body remove ammonia from the blood. In people with UCDs, ammonia buildup can lead to coma, or death, the FDA said Friday in a news release.

Ravicti is a liquid taken three times daily with meals. It's been approved for people whose disorders cannot be managed by a protein-restricted diet or amino acid supplements alone, the agency said.

Ravicti was compared to another UCD drug in a clinical study involving 44 adults. The most common side effects of the new drug were diarrhea, flatulence and headache.

Ravicti is marketed by Hyperion Therapeutics, based in South San Francisco, Calif.

More information: The U.S. National Library of Medicine has more about UCDs.

add to favorites email to friend print save as pdf

Related Stories

Marqibo approved for ph- acute lymphoblastic leukemia

Aug 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia ...

Two pancreatic-enzyme products approved

Mar 02, 2012

(HealthDay) -- Two drugs that supplement the digestion-aiding actions of pancreatic enzymes have been approved by the U.S. Food and Drug Administration, the agency said Thursday in a news release.

Marqibo approved for rare leukemia

Aug 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with a rare form of blood and bone marrow cancer, Philadelphia chromosome negative ...

Perjeta approved for advanced breast cancer

Jun 11, 2012

(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments